» Articles » PMID: 22362941

C-KIT Messenger RNA and Protein Expression and Mutations in Canine Cutaneous Mast Cell Tumors: Correlations with Post-surgical Prognosis

Overview
Date 2012 Feb 25
PMID 22362941
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Cutaneous mast cell tumors (MCTs) are among the most common neoplasms in dogs and show a highly variable biologic behavior. Histological grading, cell proliferation markers, and KIT immunohistochemistry are typically used to predict post-surgical prognosis. In the present study, c-KIT messenger RNA (mRNA) expression was measured in canine MCTs and its relationship with tumor grade, immunohistochemical staining pattern, post-surgical prognosis, and mutations was investigated. A significant increase of c-KIT mRNA was observed in MCTs versus healthy skin and surgical margins. Mutations were observed in 8.3% of cases. The KIT staining pattern was investigated for both grading systems. In particular, staining pattern III was associated with grade II (G2) and G3 MCTs, while staining patterns I and II were associated with G1 and G2 MCTs. Considering the 2-tier histological grading, the high grade was mainly associated with pattern III (71%) while the low grade was associated with patterns II (70%) and I (28%). A weak association between the KIT staining pattern and outcome was also observed. The results obtained suggest that c-KIT mRNA is overexpressed in canine MCT, although the fold variations were not associated with the protein localization or complementary DNA mutations. These observations suggested that the 3 events were independent. The histological grading and the KIT staining pattern have prognostic value as previously published. Staining pattern I could be especially helpful in predicting a good prognosis of G2 MCTs. Sequence mutations were not necessarily suggestive of a worse prognosis, but might be useful in choosing a chemotherapy protocol.

Citing Articles

Mutational Landscape of Proto-Oncogene Coding Sequence in 62 Canine Cutaneous and Subcutaneous Mast Cell Tumors.

Montanucci L, Guidolin E, Lopparelli R, Mucignat G, Pauletto M, Giantin M Vet Sci. 2024; 11(12).

PMID: 39728933 PMC: 11680137. DOI: 10.3390/vetsci11120593.


Comparison of DNA extraction methods for genotyping equine histidine-rich glycoprotein insertion/deletion polymorphisms using oral mucosa swabs and feces.

Muko R, Ojima Y, Matsuda H, Toishi Y, Oikawa M, Shin T Vet Anim Sci. 2024; 25:100361.

PMID: 38947185 PMC: 11214520. DOI: 10.1016/j.vas.2024.100361.


Clinical Use of Molecular Biomarkers in Canine and Feline Oncology: Current and Future.

Aupperle-Lellbach H, Kehl A, de Brot S, van der Weyden L Vet Sci. 2024; 11(5).

PMID: 38787171 PMC: 11126050. DOI: 10.3390/vetsci11050199.


Immunohistochemical and Molecular Genetic Analysis of Canine Digital Mast Cell Tumours.

Conrad D, Kehl A, Muller T, Klopfleisch R, Aupperle-Lellbach H Animals (Basel). 2023; 13(10).

PMID: 37238124 PMC: 10215161. DOI: 10.3390/ani13101694.


Canine mast cell tumours part I: Clinical and survival outcomes.

Tamlin V, Bottema C, Woolford L, Dobson E, Kessell A, Peaston A Vet Med Sci. 2022; 8(4):1409-1420.

PMID: 35505524 PMC: 9297790. DOI: 10.1002/vms3.812.